De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study

摘要

We investigated the clinicopathologic characteristics, treatment, and prognosis of non small-cell lung cancer patients with de novo mesenchymal-epithelial transition (MET) amplification. The results demonstrated that patients with MET amplification had a trend toward a high prevalence of the solid predominant subtype of adenocarcinoma and of brain metastases. Patients with de novo MET amplification benefit from crizotinib treatment, especially those with high-level amplification.